Managers / Q3 2023 · view latest →
Artia Global Partners LP
CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384
Summary
Artia Global Partners LP reported $241M in U.S.-listed holdings across 27 positions for Q3 2023.
The portfolio is heavily concentrated: NVO alone accounts for 25.8% of reported value.
Compared with Q2 2023, the fund opened 0 new positions and exited 7.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 54.4% · $131M
- ADR · 41.2% · $99M
- Other · 4.4% · $11M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| BIIBBIOGEN INC | SOLD OUT | −52.3K | 0 | −$15M | $0 |
| MRNAMODERNA INC | SOLD OUT | −84.7K | 0 | −$10M | $0 |
| IMGNEURIMMUNOGEN INC | SOLD OUT | −543.4K | 0 | −$10M | $0 |
| OPHTEURIVERIC BIO INC | SOLD OUT | −244.9K | 0 | −$10M | $0 |
| APLSUSDAPELLIS PHARMACEUTICALS INC | SOLD OUT | −102.9K | 0 | −$9M | $0 |
| NVONOVO-NORDISK A S | ADDED | +340.9K | 681.8K | +$7M | $62M |
| BNTXBIONTECH SE | SOLD OUT | −37.1K | 0 | −$4M | $0 |
| MOR2MORPHOSYS AG | SOLD OUT | −43.5K | 0 | −$324,938 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $499M | 50 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $706M | 55 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $631M | 51 | Nov 14, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2025 | $416M | 37 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $395M | 38 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $280M | 37 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $367M | 45 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $517M | 46 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $498M | 49 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $344M | 31 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $241M | 27 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $290M | 34 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $271M | 36 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $262M | 25 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.